Safety, Tolerability, and Clinical Assessment of Bemdaneprocel for Parkinson’s Disease: 18-Month Results From a Phase 1 Study von Fasano, A., Henchcliffe, C., Sarva, H., Lozano, A., Kalia, S., Yu, K.K.H., Brennan, C., Stemple, W., Abid, N., Yountz, M., Enayetallah, A., Lampron, A., Tabar, V.

Volltext

P-53 Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: Outcomes from the phase 3 CHAMPION-NMOSD trial von Pittock, S., Barnett, M., Bennett, J.L., Berthele, A., de Sèze, J., Levy, M., Nakashima, I., Oreja-Guevara, C., Palace, J., Paul, F., Pozzilli, C., Allen, K., Mashhoon, Y., Yountz, M., Kim, H.J.

Volltext

Consistent improvement with eculizumab across muscle groups in myasthenia gravis von Mantegazza, R, O'Brien, FL, Yountz, M, Howard, JF, study group, REGAIN, De Bleecker, Jan

Volltext

Intracellular Localization of the Fanconi Anemia Complementation Group A Protein von Walsh, Christopher E., Yountz, Marcus R., Simpson, Dennis A.

Volltext

Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension von Pittock, Sean J, Fujihara, Kazuo, Palace, Jacqueline, Berthele, Achim, Kim, Ho Jin, Oreja-Guevara, Celia, Nakashima, Ichiro, Levy, Michael, Shang, Shulian, Yountz, Marcus, Miller, Larisa, Armstrong, Róisín, Wingerchuk, Dean M

Volltext

Long-term Safety and Efficacy of Eculizumab in Neuromyelitis Optica Spectrum Disorder (1494) von Wingerchuk, Dean M., Pittock, Sean J., Berthele, Achim, Fujihara, Kazuo, Kim, Ho Jin, Levy, Michael, Palace, Jacqueline, Nakashima, Ichiro, Terzi, Murat, Totolyan, Natalia, Viswanathan, Shanthi, Wang, Kai-Chen, Allen, Kerstin, Fujita, Kenji P., Yountz, Marcus, Armstrong, Roisin

Volltext

Impact of Eculizumab on Disability Worsening and Quality of Life in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Results from the Phase 3 PRE... von Palace, Jacqueline, Pittock, Sean J., Berthele, Achim, Fujihara, Kazuo, Kim, Ho Jin, Levy, Michael, Nakashima, Ichiro, Terzi, Murat, Totolyan, Natalia, Viswanathan, Shanthi, Wang, Kai-Chen, Shang, Shulian, Yountz, Marcus, Armstrong, Roisin, Wingerchuk, Dean M.

Volltext

Benefit of Eculizumab for a Broad Range of Patients with Aquaporin-4 Antibody-positive Neuromyelitis Optica Spectrum Disorder: Findings from the Phase 3 PREVENT Study (1299) von Fujihara, Kazuo, Berthele, Achim, Kim, Ho Jin, Levy, Michael, Nakashima, Ichiro, Oreja-Guevara, Celia, Palace, Jacqueline, Pittock, Sean J., Terzi, Murat, Totolyan, Natalia, Viswanathan, Shanthi, Wang, Kai-Chen, Pace, Amy, Yountz, Marcus, Miller, Larisa, Tanvir, Imran, Armstrong, Roisin, Wingerchuk, Dean M.

Volltext

Impact of Eculizumab on Health Outcomes in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Findings from the PREVENT Study (1765) von Berthele, Achim, Pittock, Sean J., Fujihara, Kazuo, Kim, Ho Jin, Levy, Michael, Palace, Jacqueline, Nakashima, Ichiro, Terzi, Murat, Totolyan, Natalia, Viswanathan, Shanthi, Wang, Kai-Chen, Shang, Shulian, Yountz, Marcus, Armstrong, Roisin, Wingerchuk, Dean M.

Volltext

Impact of Eculizumab on Hospitalization Rates and Relapse Treatment in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: the Phase 3 PREVENT Study... von Kim, Ho Jin, Pittock, Sean J., Berthele, Achim, Fujihara, Kazuo, Levy, Michael, Palace, Jacqueline, Nakashima, Ichiro, Terzi, Murat, Totolyan, Natalia, Viswanathan, Shanthi, Wang, Kai-Chen, Pace, Amy, Fujita, Kenji P., Yountz, Marcus, Armstrong, Roisin, Wingerchuk, Dean M.

Volltext

Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-lab... von Kim, Ho Jin, Nakashima, Ichiro, Viswanathan, Shanthi, Wang, Kai-Chen, Shang, Shulian, Miller, Larisa, Yountz, Marcus, Wingerchuk, Dean M., Pittock, Sean J., Levy, Michael, Berthele, Achim, Totolyan, Natalia, Palace, Jacqueline, Barnett, Michael H., Fujihara, Kazuo

Volltext